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ABSTRACT
Objective A systematic literature review (SLR; 2009–
2014) to compare a target-oriented approach with
routine management in the treatment of rheumatoid
arthritis (RA) to allow an update of the treat-to-target
recommendations.
Methods Two SLRs focused on clinical trials employing
a treatment approach targeting a specific clinical
outcome were performed. In addition to testing clinical,
functional and/or structural changes as endpoints,
comorbidities, cardiovascular risk, work productivity and
education as well as patient self-assessment were
investigated. The searches covered MEDLINE, EMBASE,
Cochrane databases and Clinicaltrial.gov for the period
between 2009 and 2012 and separately for the period
of 2012 to May of 2014.
Results Of 8442 citations retrieved in the two SLRs,
176 articles underwent full-text review. According to
predefined inclusion/exclusion criteria, six articles were
included of which five showed superiority of a targeted
treatment approach aiming at least at low-disease
activity versus routine care; in addition, publications
providing supportive evidence were also incorporated
that aside from expanding the evidence provided by the
above six publications allowed concluding that a target-
oriented approach leads to less comorbidities and
cardiovascular risk and better work productivity than
conventional care.
Conclusions The current study expands the evidence
that targeting low-disease activity or remission in the
management of RA conveys better outcomes than
routine care.
INTRODUCTION
New treatment options and new treatment strat-
egies have changed the achievable outcomes in
rheumatoid arthritis (RA) over the last 20 years.1–5
The treat-to-target (T2T) algorithm developed in
2010 consisted of 10 recommendations advocating
the implementation of therapeutic principles, espe-
cially targeting remission or low-disease activity by
adjusting therapy in the context of regular disease
activity assessments. These recommendations were
based on evidence obtained from a systematic lit-
erature review (SLR),6 but to a large extent also on
expert opinion. The international task force of the
T2T project assumed that the evidence base for the
T2T recommendations may have expanded and
further developed and that an update was needed
especially to learn whether the expert-based state-
ments were supported or contested by new evi-
dence. Moreover, it was deemed interesting and
important by the steering committee to not only
focus on the traditional clinical, functional and
structural endpoint but also on additional aspects
related to quality of life and other outcomes
important to patients.
METHODS
In 2012 and 2014, systematic literature searches of
available evidence regarding the effects of treating
RA strategically were conducted. In addition to
testing clinical, functional and/or structural changes
as endpoints, comorbidities, cardiovascular (CV)
risk, work productivity and education as well as
patient self-assessment were investigated. In the
opinion of the steering committee, an initial search
of the 2009–2012 literature performed in 2012 did
not provide sufficient new evidence to justify an
amendment of the recommendations. A new search
on the literature published between 2012 and
5/2014 was now performed; that latter SLR focuses
also on the additional outcomes mentioned above.
SLR: UPDATE
The new SLRs are a follow-up to the SLR per-
formed by Schoels et al in 2009.6 The search strat-
egy developed then by the international steering
committee of the T2T project and described in
detail elsewhere6 was expanded by using additional
keywords (see below). Two research fellows (MMS
in 2012; MAS in 2014) performed the SLRs with
support from their mentors.
The definitions of the 2009 SLR were generally
also used for this update (with slight changes).
These were:
1. Strategy trial—clinical trial of any RA drug
treatment, in which a clear outcome target was
the primary endpoint and therapeutic conse-
quences of failing to reach the target were
predefined.
2. Targets—a target could be formulated by clin-
ical, serological, patient reported, functional or
imaging-derived variables; individual measures
(eg, joint counts or acute phase reactants), com-
posite scores (eg, disease activity score (DAS) or
simplified disease activity index (SDAI)),
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response criteria (eg, those defined by the American College
of Rheumatology (ACR) or the European League Against
Rheumatism (EULAR)), structural or ultrasound outcomes
were considered alike.
3. Outcomes—clinical, functional, serological, structural
changes and comorbidity, as defined in the respective trials,
were compared between treatment groups.6
Beyond those applied in 2009, several new keywords:
“patient-self assessment”, “comorbidities”, “cardiovascular
risk”, “work productivity” and “education” in a target-oriented
study were used. Controlled trials and observational studies
were included. The searches covered the databases MEDLINE,
EMBASE, Cochrane and Clinicaltrial.gov for the period
between 1/2009 and 5/2014. The PICOs (see online supplemen-
tary table S1) and the search strings are shown in the online
supplementary material (see online supplementary table S2 for
2012, supplementary table S3 for 2014). Like in the previous
work, the search was limited to human RA, adults and the
English language. Furthermore, we did not exclude studies
based on quality in the initial searches.
RESULTS
The first search performed in 2012 yielded 3256 hits. The search
performed in 2014 arrived at 5186 records for further investiga-
tion (figure 1). Title and abstract review according to the inclu-
sion/exclusion criteria led to assessment of eligibility of 91 and 85
full-text documents, respectively. The detailed review of the
records in relation to the primary search objectives (comparison of
primary endpoints in a priori strategy trials) resulted in the inclu-
sion of four papers7–10 from the search in 2012 and two add-
itional papers11 12 from the search performed in 2014. An
overview of the six included studies is given in table 1A. From the
identified references, we extracted information about the targets
driving treatment decisions, the interval of control examinations,
the numbers of patients included and the outcomes (table 1A).
Five of the six included studies dealt with early RA7–10 12 and
one trial with established RA.11 All studies showed a superiority
of a T2T strategy compared with routine care (RC)7 8 10–12
except for one study (Strategic Reperfusion Early After
Myocardial Infarction).9 For the included studies, the risk of
bias was assessed according to the scheme proposed by the
‘Cochrane risk of bias assessment’ (figure 2).
In early RA, the T2T strategy brought more patients into remis-
sion or low-disease activity and this was achieved more rapidly.
Also, patients in the T2T group experienced larger improvements
in patient assessments of pain, functional ability and disease activ-
ity (Dutch Rheumatoid Arthritis Monitoring (DREAM)).10 In one
trial of recent-onset active RA, the tight control approach showed
that more patients achieved remission without disability and radio-
graphic progression (Guérir la Polyarthrite Rhumatoide Débutante
(GUEPARD)/Etude et Suivi des Polyarthrites Indifférenciées
Récentes (ESPOIR)).8 Another study showed similar findings: the
DAS-driven treatment led to better clinical outcomes (health
assessment questionnaire, DAS28 and median erythrocyte sedi-
mentation rate) and numerically, but not statistically different sup-
pression of joint damage in the T2T group.7
In a study dealing with established active RA,11 physicians
were randomised into three groups (treating according to RC or
targeting a DAS28<2.6 or a swollen joint count of 0). Although
there was no difference in terms of therapeutic endpoint
achievement, the time to reach a good/moderate EULAR
response was significantly shorter and the dropout rates were
significantly lower when using the targeted approaches.11
Furthermore, using real-life data from the DREAM registry and
the Nijmegen early RA inception cohort, a T2T strategy was
found to be cost-effective compared with RC.12
Only one study did not show superior effects of a T2T strat-
egy; however, this study assessed only a small number of
patients with low radiographic damage and presented good
functional status in both treatment groups.9 Further studies are
discussed in some more detail in the online supplement S4.
Figure 1 Flow chart of the systematic literature search. Diagrammed are the results of the initial and second search (2012 and 2014, respectively)
and the selection process of abstract screening, full-text review and inclusion according to expert opinion.
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Table 1 (A) Publications comparing an a priori targeted treatment strategy with routine care; (B) supportive evidence
(A) Studies directly addressing outcomes based on different treatment strategies
Author Groups
Treatment decision
driving target Interval of control examinations N Outcomes Randomisation
Goekoop-Ruiterman
et al7
Targeted group (T) DAS≤2.4 3 months 234 Clinical outcome at 1 year Primary outcome: change damage progression by the
total SHS
Yes
Routine control
group (R)
Treatment changes left to
the discretion of the
treating doctor
3 months 201
Soubrier et al
(GUEPARD/ESPOIR)8
GUEPARD—
Targeted group (T)
LDA by DAS28ESR<3.2 3 months 65 Assessed variables: SJ, TJ, VAS pain, VAS general wellbeing, VAS physician
overall assessment, morning stiffness, ESR, CRP, HAQ, radiographs hands and
feet (SHS)
No
ESPOIR—Routine
control group (R)
Assessment at weeks 0, 24 and 52 130
Van Eijk et al
(STREAM)9
Targeted group (T) DAS(44-joint score)<1.6 3 months 42 Clinical outcome at 2 years Primary endpoint: progression of radiographic joint
damage at 2 years Secondary endpoints: difference between the two treatment
strategies after 2 years regarding DAS, the percentage of patients in clinical
remission (DAS<1.6), HAQ and adverse events
Yes
Routine control
group (R)
Treatment according to
rheumatologist´s preference
3 months 40
Schipper et al
(DREAM)10
Targeted group (T) DAS 28<2.6 Assessment at weeks 0, 8, 12, 20, 24, 36 126 Clinical outcome at 1 year Primary endpoint: percentage of patients in remission
(DAS28<2.6) Secondary endpoint: time to achieve remission, the course over
time of the DAS28, the percentage of patients with “low” disease activity
(DAS28≤3.2), the mean change in DAS28 and individual core set variables from
baseline to 1 year
No
Routine control
group (R)
Treatment at the discretion
of the treating
rheumatologist
Assessment at weeks 0, 12, 24, 36, 52 126
Pope et al11 DAS—targeted
group (T)
DAS28<2.6 Patients could be seen at any time as per
judgement of the treating physician.
Recommended visits were at 0, 2, 4, 6, 9, 12,
18 months
100 Clinical outcome at 1 year Primary endpoint: change in DAS 28 Secondary
endpoint: changes at 6, 12, and 18 months in the SJC, TJC, CRP, ESR, HAQ,
PGL, WLQ, patient satisfaction (5-point Likert scale), achievement of LDA
(DAS<3.2), disease remission (DAS<2.6), and good/moderate EULAR response
and time to achieve these end points
Cluster
randomised
0-SJC—targeted
group (T)
0-SJC Patients could be seen at any time as per
judgement of the treating physician.
Recommended visits were at 0, 2, 4, 6, 9, 12,
18 months
99
Routine control
group (R)
Treatment left at the
discretion of the treating
physician
Patients could be seen at any time as per
judgement of the treating physician.
Recommended visits were at 0, 6, 12,
18 months
109
Vermeer et al
(DREAM)12
Targeted group (T) DAS28<2.6 0, 8, 12, 20, 24, 36, 52 weeks 261 The ICER per patient in remission and ICUR per QALY were calculated over two
and 3 years of follow-up
No
Routine control
group (R)
Treatment left at the
discretion of the
rheumatologist
3 Months 213
Panel (B) Supportive evidence for differences of outcomes depending on reaching different endpoints
Author Patients Target/outcome Conclusion Randomisation
Targeting cardiovascular risk
Crowson et al24 Review n.a. Suppression inflammation—may also reduce risk of heart disease; investigations of the innate and
adaptive immune responses occurring in RA may delineate novel mechanisms in the pathogenesis of heart
disease and help identify novel therapeutic targets for the prevention and treatment of heart disease
Therapies used to treat RA may also affect the development of heart diseases, by suppressing
inflammation, they may also reduce the risk of heart disease. Therapies used to treat RA may also affect
the development of heart diseases, by suppressing inflammation, they may also reduce the risk of heart
disease
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Table 1 Continued
Panel (B) Supportive evidence for differences of outcomes depending on reaching different endpoints
Author Patients Target/outcome Conclusion Randomisation
Work/productivity
Rantalaiho et al20 195 Strict remission rates at 6, 12 and 24 months as well
as the cumulative work disability days up to 5 years in
these four subgroups
Using targeted treatment with monotherapy may well substitute for using combination DMARDs, but to
benefit as many early RA patients as possible both approaches are necessary. Targeted treatment strategy
is beneficial irrespective of the type of therapy
Yes
Smolen et al21 834 enrolled—604
eligible for double-blind
period
Sustained LDA Conventional or reduced doses of etanercept with MTX in patients with moderately active RA more
effectively maintain LDA than does MTX alone after withdrawal of etanercept
Yes
Radner et al19 356 Physical function, health-related quality of life, work
productivity, estimation of direct and indirect costs
Patient with remission show better function, health-related quality and productivity, even when compared
with another good state, such as LDA. Also from a cost perspective, remission appears superior to all
other states
No
Education
Pope et al25 1000 serial RA charts SDAI Small group learning with feedback from practice audits is an inexpensive way to improve outcomes in RA Cluster
randomised
Additional evidence
Thiele et al28 6864 DAS28 (Boolean/SDAI) Patients fulfilling the new remission criteria tend to be not only free from active RA, but also from other
disabling diseases. If these criteria are applied in clinical practice to guide treatment decisions, the impact
of comorbidity should be taken into account
No
Vermeer et al29 409 DAS28, HAQ, SF36, MCS, SHS In very early RA, T2T leads to high (sustained) remission rates, improved physical function and
health-related quality of life, and limited radiographic damage after 3 years in daily clinical practice
No
Sakellariou et al30 166 SDAI, DAS28, HAQ, PDPS The new remission definitions confirmed their validity in an observational setting and identify patients
with better disease control.
No
Balsa et al31 97 SDAI The results suggest that the SDAI classification of remission is closer to the concept of an absence of
inflammatory activity, as defined by the absence of positive PD signal by US
No
Dale et al32 111 DAS44, HAQ, MRI (RAMRIS), X-ray hands + feet MSUS disease activity assessment was not associated with improved clinical outcomes except a higher rate
of DAS44 remission after 18 months.
Target US sonographic remission does not appear to be superior to clinical LDA
Yes
Dale et al33 53 DAS28 Compared to the DAS28, global RA disease activity assessment using a limited MSUS joint set provided
additional disease activity information and led to altered treatment decisions in a significant minority of
occasions. This may allow further tailoring of DMARD therapy by supporting DMARD escalation in patients
with continuing subclinical synovitis and preventing escalation in symptomatic patients with minimal
clinical and/or ultrasonographic synovitis
No
CRP, C reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; DREAM, Dutch Rheumatoid Arthritis Monitoring; ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes; ESR, erythrocyte sedimentation rate;
GUEPARD, Guérir la Polyarthrite Rhumatoide Débutante; HAQ, health assessment questionnaire; ICER, incremental cost-effectiveness ratio; ICUR, incremental cost utility ratio; LDA, low-disease activity; MCS, mental component summary; MSUS,
musculoskeletal ultrasound; MTX, methotrexate; PDPS, power Doppler-positive synovitis; PD, power Doppler; PGL, patient global assessment of disease activity; QALY, quality-adjusted life-year; RA, rheumatoid arthritis; RAMRIS, rheumatoid arthritis MRI
joint space narrowing score; SDAI, simplified disease activity index; SF36, short form 36 physical component summary; SHS, Sharp/van der Heijde radiographic score; SJ, swollen joint; SJC, swollen joint count; STREAM, Strategies in Early Arthritis
Management TJ, tender joint; TJC, tender joint count; T2T, treat to target; US, ultrasound; VAS, visual analogue scale; WLQ, work limitations questionnaire.
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Regarding comorbidities, CV risk, work productivity or the
role of (patient) education, none of the studies comparing T2T
to RC had any of these outcomes as primary endpoint.
However, these outcomes were addressed in observational data
or registry studies comparing different strategic treatment
approaches and endpoints, and therefore, these publications
were regarded as further supporting evidence and are presented
in table 1B.
Subanalysis of PREMIER (a multicenter, randomised, double-
blind clinical trial of combination therapy with adalimumab plus
methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not
had previous methotrexate treatment) and Active-Controlled
Study of Patients Receiving Infliximab for the Treatment of
Rheumatoid Arthritis of Early Onset (ASPIRE) data showed that
the level of disease activity, the duration of SDAI remission and
latency to remission all affect radiographic progression.13 There
is a direct relationship between disease activity and radiographic
changes but a dissociation of the effect with tumour necrosis
factor inhibitor use.14 Among these publications were studies
showing that Clinical Activity Disease Index remission is asso-
ciated with lower CV risk and improved CV outcomes,15 16 and
the absence of swollen joints with improved overall survival.17
Additional studies that emerged during the SLR were cate-
gorised by topics and also presented to the task force. All these
studies are listed in the online material (see online supplemen-
tary table S5).
Aside from the work of Pope et al,11 all of the above-
described articles studied patients with early RA. However,
Gullick et al18 investigated an observational cohort of patients
with long-standing RA in a setting of usual care. In their study,
the authors compared the outcomes of an RA centre routinely
using goal-directed therapy aimed at DAS28<2.6 with an age-
matched and sex-matched sample of consecutive patients from
other RA clinics. Significantly more T2T patients achieved the
target, irrespective of their disease duration, and T2T led to sig-
nificantly improved functional outcomes compared with RC.
DISCUSSION
Since the original search informing the T2T task force, six
new studies have been published, five of which fully support
that a treatment strategy using a defined target conveys super-
ior clinical, functional and structural outcomes compared with
RC. In contrast to the data available in 2010, now more
studies have used clinical remission defined by DAS or DAS28
as a main endpoint, which is a more stringent target than low-
disease activity. While trials directly comparing potential dif-
ferences in targeting remission versus low-disease activity are
not available, supportive evidence exists that reaching ACR–
EULAR remission is superior in terms of physical function,
quality of life and work productivity and significant differ-
ences ensue when moving from one of these desired states to
the other.19
In 2010, studies evaluating target-steered versus non-steered
treatment approaches were only available for early RA. The new
search revealed additional investigations on early or even
recent-onset RA, but also data on established RA. Indeed, infor-
mation on target steered therapy in established RA was a point
in the research agenda in 2010; the data reveal that also in long-
standing RA a T2T strategy is superior to RC.11 18
Finally, some new aspects were evaluated here, namely work
productivity, comorbidities and effect of education on treatment
Figure 2 Rick of bias summary
figure. +Low risk of bias, −High risk of
bias, ?Unclear risk of bias, n.a. Not
applicable. *In the study of Pope et al
physicians were randomised.
**Vermeer et al was comparing real
life data from cohorts.
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outcomes. While trials comparing different therapeutic strat-
egies using these outcomes as primary endpoints are not yet
available, secondary analyses reveal that lower disease activity is
associated with better work productivity, less comorbidity and
CV risk and that better education is likewise related to better
clinical outcomes.11 15 16 19–25 The task force was informed
about these data as supportive evidence.
The present SLR provided new evidence regarding several
items of the 2010 T2T recommendations,26 which allowed to
update the recommendations as presented in the paper by
Smolen et al.27 Indeed, the evidence base of several items
increased from D to B or A (for details, see main paper) and
several items, such as the overarching principle B and points 1
and 3 (with respect to established RA), as well as point 7, could
be amended or expanded based on this new SLR. In conclusion,
new and expanded evidence has been identified confirming that
treating RA to a target of low-disease activity or remission
enables patients to reach better outcomes than when they are
exposed to RC. This information was provided to and discussed
in detail by the task force allowing to develop an update of the
T2T recommendations with much higher levels of evidence.27
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